• ISSN 2320-0901 (Online)
  • Monthly since 2012
  • Open access
  • Double blind peer review
editor@ijrmp.org
IJRMP International Journal for Research in Management & Pharmacy Published by ResaGate Global
Submit manuscript

Post-Acute Outcomes in Ensovibep-Treated COVID-19 Patients: A 6-Month Prospective Observational Study

Research articleOpen accessVol. 6, Issue 9, August 2017

  • Pratima SharmaIndependent Researcher, Maharashtra, India
Published
31 August 2017
Licence
CC BY 4.0
Download PDFHow to citeDownload citation (RIS)BibTeX

How to cite

Pratima Sharma (2017). Post-Acute Outcomes in Ensovibep-Treated COVID-19 Patients: A 6-Month Prospective Observational Study. International Journal for Research in Management & Pharmacy, 6(9).

Abstract

The emergence of COVID-19 demanded novel therapeutic agents to mitigate both acute infection and long-term complications. Ensovibep, a designed ankyrin repeat protein (DARPin) antiviral therapeutic, showed promising efficacy in early infection management. However, its impact on long-term post-acute COVID-19 symptoms remains underexplored. This prospective study aimed to evaluate the 6-month post-acute outcomes among COVID-19 patients treated with Ensovibep compared to standard-of-care controls, focusing on respiratory, cardiovascular, neurocognitive, and quality-of-life parameters. A total of 240 PCR-confirmed COVID-19 patients were enrolled at two tertiary care centers. Of these, 120 received Ensovibep during the acute phase, while 120 matched controls received standard care. Data were prospectively collected on post-acute sequelae using symptom inventories, spirometry, echocardiography, Montreal Cognitive Assessment (MoCA), and SF-36 quality-of-life scores at 3 and 6 months post-discharge. Ensovibep-treated patients exhibited significantly reduced incidence of dyspnea (17.5% vs. 32.5%, p < 0.05), cognitive impairment (MoCA < 25: 11.7% vs. 24.2%), and fatigue (20.8% vs. 38.3%) at 6 months. Quality-of-life scores across physical and mental domains were higher in the Ensovibep group. Cardiopulmonary assessments also showed reduced prevalence of post-viral myocarditis and pulmonary function abnormalities. Ensovibep administration during the acute phase of COVID-19 was associated with improved post-acute recovery and fewer long-COVID symptoms over 6 months. These findings support its role in early intervention to limit prolonged morbidity.

Keywords: COVID-19; Ensovibep; post-acute sequelae; long COVID; DARPin therapeutics; prospective cohort; quality of life; neurocognitive outcome; observational study; antiviral therapy

References

  • Carfì A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603-605. doi:10.1001/jama.2020.12603
  • Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19. MMWR Morb Mortal Wkly Rep. 2020;69(30):993-998. doi:10.15585/mmwr.mm6930e1
  • Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet. 2021;397(10270):220-232. doi:10.1016/S0140-6736(20)32656-8
  • Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from COVID-19. JAMA Cardiol. 2020;5(11):1265-1273. doi:10.1001/jamacardio.2020.3557
  • Logue JK, Franko NM, McCulloch DJ, et al. Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw Open. 2021;4(2):e210830. doi:10.1001/jamanetworkopen.2021.0830
  • Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601-615. doi:10.1038/s41591-021-01283-z
  • Walser M, Rothenberger S, Herling T W, et al. Highly potent anti–SARS-CoV-2 multi-DARPin therapeutic candidate ensovibep (MP0420) retains efficacy against Omicron. Nat Biotechnol. 2022;40(2):184-190. doi:10.1038/s41587-021-01160-w
  • Gottlieb RL, Vaca CE, Paredes R, et al. Ensovibep for treatment of outpatients with COVID-19. N Engl J Med. 2022;386(19):1722-1730. doi:10.1056/NEJMoa2202373
  • Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Sci Rep. 2021;11:16144. doi:10.1038/s41598-021-95565-8
  • Douaud G, Lee S, Alfaro-Almagro F, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022;604:697-707. doi:10.1038/s41586-022-04569-5

How to cite

Pratima Sharma (2017). Post-Acute Outcomes in Ensovibep-Treated COVID-19 Patients: A 6-Month Prospective Observational Study. International Journal for Research in Management & Pharmacy, 6(9).

Licence

This article is open access, published under the CC BY 4.0 licence. Copyright remains with the authors.

If the issue persists, you can use the old publisher details where you get it published.